Venture Philanthropy: The New Venture Capital?
This article was originally published in Start Up
Executive Summary
Non-profit organizations' growing support for industry drug development does more than fill a funding gap. It brings disease-knowledge, patient-access and an understanding of the end-market that few traditional VCs can offer.
You may also be interested in...
Deals Of The Week Searches For Meaning In Deal Break-Ups
Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.